Mana.bio

This week Mana.bio was the season premiere episode for season 2 of Surani Fernando's Raising Biotech. Surani took the time to fully explore and bring to life our multi-layered start-up story including our origin, science and the challenges of launching the organization from stealth in October 2023 in the midst of the attacks on Israel. You will hear from our CEO, Yogev Debbi about his background, the fundraising journey and what it's like becoming a Wartime CEO, as well as our advisor and pharma veteran Barry Ticho MD, PhD on our scientific thesis, competitive edge and future potential to advance the world of gene therapy. You can listen to the podcast here: https://lnkd.in/dx3M6r-U Roy Nevo Avi Schroeder Kira Radinsky a16z Bio + Health NFX LionBird Base4 Capital Technion - Israel Institute of Technology #techbio #lipidnanoparticles #wartimeCEO #wedeliver #nomatterwhat

Our CEO, Yogev Debbi will be speaking at Bio-Europe Spring next week on March 18th at 3 pm local time. If you're registered, please consider attending and be sure to say hello. 

Our CEO Yogev Debbi spoke with David Matthews of Science|Business on the fight to keep Israel at the forefront of science and technology. “We have to show that part of winning the war is not only winning the war on the battlefield, which is what our brave soldiers will do,” Debbi said. “It's also about […] keeping Israel at the forefront of science and technology.”[...] Debbi argues it’s in the wider interest to keep the country at the technological edge. “It’s good not only for Israel, but also for the world, because Israel is one of the biggest producers of patents and technology innovations. So I think people can relate to that, regardless of the political questions.” Read the full article here: https://lnkd.in/drptxfiZ #biotechnology #innovation #Israel 

Thanks Omri Amirav-Drory and NFX team of your continued support and being part of Mana.bio journey. Read below to learn more why our investors are excited by our approach of leveraging AI to unlock drug delivery.

Thank you to Ron Miller and TechCrunch for sharing our exciting news and making the community aware of the challenges we currently face in Israel. “It’s really, really hard [to launch a startup], and with all the sadness and the bad news that you hear all day long, we as a company, have the privilege and also the commitment to continue pushing forward the business,” Debbi said. “And this is a very important signal to the team, to the country and to the world.” Learn more: https://lnkd.in/d_rHtfUQ

Thank you to Ryan Cross and Endpoints News for highlighting the work that Mana.bio has achieved through our funding and research. We look forward to continuing our efforts to make an impact and unlock the potential for new genetic therapies across a wide range of unmet needs. https://lnkd.in/gReHpKkm

We are proud to share the closure of an oversubscribed $19.5M seed round co-led by Andreessen Horowitz a16z Bio + Health, Base4 Capital, NFX, LionBird and Technion - Israel Institute of Technology. We are also unveiling our AI-based lipid nanoparticle delivery platform to accelerate the development of nucleic acid-based therapeutics and vaccines. The financing enables us to advance development of our AI LNP platform to deliver RNA and gene therapies more safely and effectively to specific extrahepatic tissues in the body, unlocking the potential for new therapies across a wide range of unmet needs. Read the full release and meet our team via https://lnkd.in/eFNV-Um4

An amazing opportunity to define how we do science, come join us!